Napan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Napan

Napan is a medication whose active ingredient is Mefenamic Acid. It is chemically categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID), a class of synthetic compounds widely used for their analgesic, anti-inflammatory, and antipyretic properties.


Property Description
Active ingredient Mefenamic Acid
Form Capsules (Oral)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic organic compound

What Type of Medicine is Napan?

Napan is classified as an NSAID, specifically belonging to the distinct fenamate subgroup, which distinguishes its chemical structure from other common pain relievers. The active component, Mefenamic Acid, is a synthetic organic compound derived from anthranilic acid. This classification indicates that the medicine functions systemically to modulate the body's processes related to discomfort. Its efficacy in treating acute pain conditions is clinically recognized and supported by pharmacological studies. The medication provides pain relief by targeting the underlying mechanisms of discomfort.

Composition and Pharmaceutical Form

The pharmaceutical product Napan is supplied as a single-ingredient capsule designed for oral administration. Each capsule contains only the active substance, Mefenamic Acid, along with necessary pharmaceutical-grade excipients that ensure stability and allow for effective absorption through the digestive system. Napan is typically a prescription-only (Rx) medication, distinguishing it from many over-the-counter NSAIDs. This formulation offers a convenient and consistent delivery of the synthetic compound into the body, particularly when rapid, short-term relief is indicated.

Napan's General Purpose in Symptom Relief

The general purpose of Napan is the symptomatic relief of discomfort by addressing the core signs of acute conditions: pain, inflammation, and fever. It achieves this by acting as an inhibitor of prostaglandin synthesis, a key step in the body's pain and inflammatory response pathway. The medication is indicated for providing short-term symptomatic relief. This means the medication offers general assistance in managing elevated body temperature and mild to moderate symptomatic distress.

What side effects are possible with Napan?

Possible Side Effects and Safety Information

Napan, containing Mefenamic Acid, is associated with an official safety profile consistent with its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID). This profile is organized in regulatory documents by frequency and the body's physiological systems involved.


Adverse Reaction Classifications

Common adverse reactions, based on regulatory labeling, frequently involve the Gastrointestinal Disorders and Nervous System Disorders. These typically include diarrhea, abdominal pain, nausea, vomiting, dyspepsia, headache, and dizziness.

More clinically significant reactions, generally categorized as rare, may affect the Blood and Lymphatic System, the Renal and Urinary System, and the Hepatobiliary System. The official safety documents also classify serious and severe skin reactions (such as Stevens-Johnson Syndrome) and other hypersensitivity reactions.


Serious Safety Considerations

The most serious documented safety concerns include the potential for life-threatening Gastrointestinal Bleeding, Ulceration, or Perforation, which can occur without warning symptoms at any time during use. The medicine is also associated with an increased risk of serious Cardiovascular Thrombotic Events, such as Myocardial Infarction and Stroke, which may occur early in treatment, and this risk is generally higher with longer duration of use.

Official labeling contains specific restrictions and limitations, including a contraindication for use in patients who have undergone coronary artery bypass graft (CABG) surgery and those with severe, pre-existing organ failures (renal, hepatic, or heart failure). Older adults are noted in regulatory information to be at a greater risk for serious gastrointestinal and renal adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Napan

Regulatory documentation defines the manifestations of Mefenamic Acid overdose as potentially severe, affecting the Central Nervous System (CNS), Gastrointestinal (GI) System, and Renal System. Documented presentations include neurological symptoms such as seizures, coma, confusional state, hallucinations, and vertigo. Gastrointestinal effects may involve nausea, stomach pain, and the occurrence of bloody vomit or black/tarry stools. Overdose has been reported to lead to fatalities and serious systemic outcomes like acute renal failure.

Mandated Emergency Actions

The regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Emergency services must be called immediately if the affected individual has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened.

Supportive Management and Monitoring

Management is strictly symptomatic and supportive, as no specific antidote is known. The official procedures described include immediate stomach emptying via gastric lavage or emesis, followed by the administration of activated charcoal. Continuous monitoring and support of vital functions is required throughout the management process due to the potential for severe systemic complications.

Therapeutic Uses of Napan

What Napan Treats: Main Uses and Benefits

Napan (Mefenamic Acid) is relevant in contexts marked by increased discomfort or tension, commonly used for managing symptoms related to mild to moderate acute pain, associated inflammation, and fever. It is applied in clinical settings that involve acute or unstable symptom patterns, when short-term symptomatic assistance is needed to help maintain functional stability. This medication is specifically indicated for the management of mild to moderate acute pain and is relevant in contexts involving primary dysmenorrhea.


Key Therapeutic Domains

This medication is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden in acute episodes. The medication is relevant for managing symptoms that interfere with daily comfort during menstrual cycle distress, including the intense cramping pain of primary dysmenorrhea, and to assist with the management of symptoms that create noticeable physiological strain, such as menorrhagia.

It is applied in situations involving recurrent or episodic manifestations, providing a supportive therapeutic benefit during times of acute discomfort. The medication is used to help address symptoms related to acute manifestations such as headaches, dental pain, general muscular aches, and symptomatic episodes tied to rheumatoid arthritis and osteoarthritis. Additionally, it is used for managing the symptom of fever (pyrexia). This helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Used for Managing Menstrual Cramps

Eligibility and Restrictions for Use

Who Can and Cannot Use Napan? (Mefenamic Acid)

This section defines the official population eligibility and non-eligibility rules for Napan, as stated in government regulatory documents.


Eligible and Restricted Populations

Napan (Mefenamic Acid) is labeled for use in adults and adolescents 14 years of age. Use is not recommended for children younger than 14 for the labeled indications. Older adults (65 years) may use the medicine but require caution and close monitoring due to an increased risk of serious adverse effects.


Absolute Contraindications

Napan is contraindicated and must not be used in patients with the following conditions or history:

  • Known hypersensitivity to Mefenamic Acid or a history of NSAID cross-sensitivity (e.g., aspirin-induced asthma or urticaria).
  • Active ulceration or chronic inflammation of the upper or lower gastrointestinal tract (e.g., Ulcerative Colitis, Crohn's disease), or history of GI bleeding related to previous NSAID therapy.
  • Severe uncontrolled heart failure, severe renal failure, or severe hepatic failure.
  • Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Physiological State Restrictions

  • Pregnancy: Use is contraindicated during the last trimester (from 30 weeks gestation).
  • Lactation: Use is not recommended for nursing mothers.
  • Fertility: The medicine may impair female fertility and is not recommended for women attempting conception.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The documented interaction profile for Mefenamic Acid is defined by its effects on pharmacodynamics and metabolism. Co-administration with oral anticoagulants (e.g., Warfarin) and anti-platelet agents enhances their activity, leading to an officially documented increased risk of bleeding. Similarly, combining Napan with Corticosteroids or SSRIs may raise the risk of gastrointestinal bleeding.

Mefenamic Acid can inhibit the renal clearance of certain medicines, resulting in elevated plasma concentrations of drugs such as Lithium and Methotrexate. This effect is also noted with oral hypoglycemic agents, where Mefenamic Acid can inhibit their metabolism, increasing the risk of hypoglycemia.

Official regulatory labeling establishes several restrictions. Napan is contraindicated for the treatment of peri-operative pain in the setting of CABG surgery, and co-administration with other systemic non-aspirin NSAIDs should be avoided. A specific timing separation is mandatory when taken with Mifepristone; Napan must not be administered for 8–12 days afterward.

Interactions can also be influenced by substance type and population. Co-ingestion of Magnesium Hydroxide antacids significantly increases the absorption of Mefenamic Acid. Consumption of alcohol may increase the risk of gastrointestinal complications. The risk of renal deterioration resulting from interactions with antihypertensives is particularly noted in the elderly or those with impaired renal function.

Mechanism of Action

Molecular Inhibition of Prostaglandin Synthesis

The core action of Napan is to act as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. By binding to these enzymes, the drug prevents them from converting arachidonic acid into prostaglandins ( PGE2), which are key biochemical mediators. This suppression of the upstream synthesis step limits the overall availability of these inflammatory signaling molecules in the body.

Modulating Peripheral and Central Signaling

The reduction in prostaglandin levels alters physiological signaling by influencing both the peripheral and central nervous systems. Peripherally, it dampens the sensitization of nociceptors (pain-sensing nerves) that is normally amplified by prostaglandins, raising the activation threshold required for afferent nerve impulse transmission. Centrally, the mechanism removes the prostaglandin signal that acts on the hypothalamic thermoregulatory center, which mediates the adjustment of the hypothalamic thermal set-point. This dual action results in systemic and localized physiological modulation.

Dosage and Administration Information

How to Use Napan

This section outlines the general administration profile for Napan (Mefenamic Acid).


Administration and Dosage Regimen

Napan is strictly for oral administration, typically supplied as capsules or tablets, and must be swallowed whole. The medicine is taken following a standardized dosing schedule and is not intended for continuous, long-term use.

Usage Parameter Parameters
Route of Administration Oral
Standard Initial Dose 500 mg (single dose)
Standard Maintenance Dose 250 mg every 6 hours
Maximum Course Duration Typically limited to 7 days for acute pain

Procedural Instructions and Timing

To ensure proper administration, the medicine should be taken with food or milk. The maximum daily dose should not exceed 1000 mg. This four-times-daily pattern maintains consistent drug levels when used for conditions requiring short-term intervention.

For indications such as primary dysmenorrhea, the drug is used cyclically, with administration commencing at the onset of symptoms or bleeding and generally continuing only for the duration of the symptomatic period, typically two to three days. If a dose is missed, it is recommended to resume the schedule at the next designated time; a missed dose should not be doubled.

Usage in older adults generally requires the use of the lowest effective dose for the shortest period.

Recent Clinical Evidence

Napan: Overview of Clinical Studies


Research Evidence for Primary Dysmenorrhea (Menstrual Cramps)

The research exploring Mefenamic Acid for primary dysmenorrhea—painful menstruation without an underlying cause—is largely built upon controlled clinical studies. Researchers primarily used Randomized Controlled Trials (RCTs) and systematic reviews exploring how symptoms change over time when compared to a placebo or other standard medications. These studies included adult women and adolescents who reported fluctuating or episodic manifestations of menstrual pain. Outcomes related to physical discomfort were measured using standardized pain scales and by monitoring the patient-reported outcomes describing perceived discomfort. The research primarily focused on measuring short-term outcomes, typically over just one to three menstrual cycles.

Research Evidence for Mild to Moderate Acute Pain

Research for mild to moderate acute pain comes from studies that examined symptom intensity or variability across different contexts, such as dental pain or musculoskeletal discomfort. Researchers utilized very short-term RCTs, often involving single doses or treatment courses lasting up to seven days, reflecting the short-term focus of the regulatory evidence base for acute pain. The populations studied were typically adults presenting with acute or disruptive episodes. Findings describe patterns observed in the studies related to measurements of pain intensity and the time intervals monitored by researchers for initial changes.

Research Gaps and Areas of Uncertainty

Key limitations consistently noted in the literature are that follow-up durations were limited across nearly all indications. The focus of the available research remains on measuring episodic or acute changes, leaving long-term outcomes not well characterized. Furthermore, comparative evidence against newer pharmaceutical or non-pharmaceutical options is sometimes lacking or relies on older studies. Data for certain subgroups, such as older adults or those with complex coexisting health issues, remain insufficient for independent conclusions.

Frequently Asked Questions (FAQ)

Common questions about Napan (FAQ)


Q: How quickly does Napan start working?

A: Information derived from the study of how the drug moves through the body indicates that the highest level of the medicine in the blood, known as the peak concentration, occurs approximately 2 to 4 hours after it is taken orally. This pharmacological data describes the general timing of the drug's peak presence in the body.


Q: Are there any long-term side effects from taking Napan?

A: Regulatory warnings state that the potential risk for serious problems, such as cardiovascular events or severe gastrointestinal bleeding, may increase with a longer duration of use. The drug's official labeled use is typically limited to a course of 7 days.


Q: Is it safe to take Napan with a multivitamin?

A: Specific drug interaction studies with general multivitamin formulations are typically not detailed in the official regulatory labeling. As a general precaution regarding supplements, official caution advises users to disclose the use of all supplements to a healthcare professional.


Q: Can Napan affect birth control pills?

A: Official interaction information notes that combining the active ingredient with certain types of oral contraceptives—specifically those containing drospirenone—may potentially increase potassium levels. It is important that the prescribing professional is made aware of all medications being used.


Q: Is it normal to feel tired after taking Napan?

A: Official regulatory information lists drowsiness as a common nervous system side effect. Additionally, unusual tiredness or weakness is noted among the potential adverse reactions that users may experience during treatment. Any experienced effects should be noted by the user.


Q: Can Napan be crushed or split?

A: The medicine is formulated as a capsule for oral administration and is described in the product information as needing to be swallowed whole. It is typically not recommended to be physically altered (crushed, split, or opened) unless explicitly directed by a healthcare professional.


Q: Why do some people need to take Napan with food?

A: The official instructions for administration require the medicine to be taken with food or milk. This timing is generally described as a method to help minimize the potential for common gastrointestinal side effects, such as stomach upset or pain.


Q: Can Napan interact with herbal supplements?

A: Official regulatory documents indicate that specific interaction studies with herbal supplements have not been conducted. For this reason, official caution advises that the possibility of altered safety or effectiveness should be considered when herbal supplements are taken alongside Napan.


Q: What research is available about Napan's use for joint swelling?

A: Research has been conducted examining the medicine's effect in conditions with inflammatory symptoms, such as rheumatoid arthritis. Researchers monitored outcomes related to spontaneous pain, joint swelling, and mobility in these studies to measure the drug's effect.


Q: Are there any studies comparing Napan to a placebo?

A: The research evidence base for primary dysmenorrhea includes analysis from Randomized Controlled Trials (RCTs). These clinical studies specifically compared the medicine to a placebo to evaluate differences in patient-reported outcomes.


Q: Is Napan known to interact with caffeine?

A: Pharmacological data suggests that combining the active ingredient with caffeine may decrease the way the body processes the medication, specifically its metabolism. This is a point noted in professional reference resources regarding potential interactions.


Q: Is it normal for Napan to change the color of urine?

A: The official list of adverse reactions includes potential changes to the urine, such as it becoming cloudy or discolored. Regulatory documents state this is a symptom noted as requiring consultation with a healthcare professional.


Q: Does taking Napan help with muscle stiffness?

A: As an anti-inflammatory drug, Napan is used to relieve discomfort. Research examining the medicine's effect in inflammatory conditions like rheumatoid arthritis included the monitoring of outcomes related to spontaneous pain and symptoms such as morning stiffness.


Q: What happens if Napan expires?

A: Official regulatory guidance mandates that expired medicine should not be used. Official regulatory instructions for disposal recommend using a community drug take-back program or following specific guidelines for safe disposal.


Q: What is the half-life of Napan?

A: Pharmacokinetic data indicates that the medicine's elimination half-life—the time it takes for half of the drug to be eliminated from the body—is approximately two to four hours.


Q: Is Napan listed on the FDA's list of shortages?

A: The status of drug supply is officially tracked by the FDA, which maintains a public database for drug shortages. This resource provides current, regulatory-sourced information about the availability of medications.


Q: Do studies show Napan is effective for headaches?

A: Yes, official regulatory documentation lists Mefenamic Acid as indicated for the relief of mild to moderate acute pain, including specific pains such as a headache and migraine.


Q: What is the risk of an allergic reaction to Napan?

A: The medicine is contraindicated (must not be used) in patients with a known history of hypersensitivity or severe allergy to the active ingredient. Adverse reactions such as a rash, swelling, or trouble breathing are noted as serious symptoms that should be reported immediately.


Q: How is Napan removed from the body?

A: Pharmacokinetic data indicates that the active ingredient and its metabolites are primarily eliminated from the body by the kidneys. A smaller amount of the medication is also eliminated via the fecal route.


Q: Why is Napan often prescribed instead of an over-the-counter option?

A: Napan is classified as a prescription-only (Rx) medication. This status reflects that its risk profile and intended short-term use require it to be administered under the oversight of a healthcare professional.


Q: What is the active ingredient's full chemical name in Napan?

A: The active ingredient, Mefenamic Acid, is a synthetic organic compound. Its calculated IUPAC chemical name, used by regulatory agencies for identification, is: methyl 2-(N,2,3-trimethylanilino)benzoate.

How should Napan be stored and disposed of?

How to Store and Dispose of Napan (Mefenamic Acid)

Official Storage Requirements

Napan (Mefenamic Acid) capsules must be stored under controlled conditions as specified in regulatory labeling to maintain product stability and safety. The medication is required to be stored at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C), and must not be stored above 30 C.

  • Protection: The product must be kept away from moisture (e.g., not in the bathroom), excess heat, and protected from light. It is essential to keep from freezing.
  • Container and Child Safety: Store the medication in its original container with the cap tightly closed. As a mandatory safety instruction, Napan must be kept out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance recommends disposing of unused or expired Napan through a community drug take-back program or mail-back envelope. If such programs are unavailable, the medication may be mixed with an undesirable substance (e.g., dirt or used coffee grounds), placed into a sealed bag or container, and discarded in the household trash, ensuring all personal information is removed from the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Napan found in:

A-Z Index: